A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells

Leukemia

Volumn 17, Issue 9, 2003, Pages 1794-1805

  Martelli, A M ^a,b   Tazzari, P L ^c   Tabellini, G ^a   Bortul, R ^d   Billi, A M ^a   Manzoli, L ^a   Ruggeri, A ^a   Conte, R ^c   Cocco, L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Acute leukemia; Apoptosis; PI3K; Resistance; Signal transduction pathways; Thorapeutic treatment

Indexed keywords

1LEVO 6 HYDROXYMETHYLINOSITOL 2 O METHYL 3 O OCTADECYLCARBONIC ACID; 2 MORPHOLINO 8 PHENYLCHROMONE; CARBONIC ACID DERIVATIVE; CASPASE 8; CASPASE 9; CYTARABINE; ETOPOSIDE; IMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE C ZETA; PROTEIN KINASE INHIBITOR; RETINOIC ACID; S6 KINASE; SERINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; WORTMANNIN;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL ACTIVITY; CELL STRAIN K 562; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; IONIZING RADIATION; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

EID: 0141502209     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403044     Document Type: Article

References (63)

1. Pui C-H. Acute lymphoblastic leukemia in children. Curr Opin Oncol 2000; 12: 3-12.
2. Tzortzatou-Stathopoulou F, Papadopoulou AL, Moschovi M, Botsonis A, Tsangaris GT. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy. J Pediatr Hematol Oncol 2001; 23: 591-597.
3. Cripe LD, Hinton S. Curr Treat Options Oncol 2000; 1: 9-17
4. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42-49.
5. Fenaux P, Chomienne C, Degos L. Acute promyelocytic leukemia: from genetics to treatment. Semin Oncol 1997; 24: 92-102.
6. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemayer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001; 7: 680-686.
7. O'Gorman DM, Cotter TG. Molecular signals in anti-apoptotic survival pathways. Leukemia 2001; 15: 21-34.
8. Gallagher RA. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia 2002; 16: 1940-1958.
9. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 2001; 11S: S22-S26.
10. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001; 26: 657-664.
11. Cantrell DA. Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001; 114: 1439-1445.
12. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 114: 2903-2910.
13. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-395.
14. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000; 60: 5451-5455.
15. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986-3997.
16. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001; 20: 6073-6083.
17. O'Gorman DM, McKenna SL, McGahon AJ, Knox KA, Cotter TG. Sensitisation of HL60 human leukaemic cells to cyotoxic drug induced apoptosis by inhibition of PI3-kinase survival signal. Leukemia 2000; 14: 602-611.
18. Cataldi A, Zauli G, Di Pietro R, Castorina S, Rana R. Involvement of the pathway phosphatidylinositol-3-kinase/AKT-1 in the establishment of the survival response to ionizing radiation. Cell Signal 2001; 13: 369-375.
19. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002; 21: 5673-5683.
20. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001; 70: 535-602.
21. Saltiel AR, Pesin JE. Insulin signaling pathways in time and space. Trends Cell Biol 2002; 12: 65-71.
22. Zick Y. Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol 2002; 12: 437-441.
23. Hu Y, Qiao L, Wang S, Rong S, Meuill et EJ, Berggren M et al. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate block PI3-K, Akt and cancer cell growth. J Med Chem 2000; 43: 3045-3051.
24. Tazzari PL, Cappellini A, Bortul R, Ricci F, Billi AM, Tabellini G et al. Flow cytometric detection of total and serine 473 phosphorylated Akt. J Cell Biochem 2002; 86: 704-715.
25. L up-regulation. Leukemia 2003; 17: 379-389.
26. Neri LM, Borgatti P, Tazzari PL, Bortul R, Cappellini A, Tabellini G et al. The phosphoinositide 3-kinase/AKTR1 pathway involvement in multidrug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res 2003; 1: 234-246.
27. Kozikowski AP, Kiddle JJ, Frew T, Berggren M, Powis G. Synthesis and biology of 1D-3-deoxyphosphatidylinositol-3-phosphate: a putative antimetabolite of phosphatidylinositol-3-phosphate and an inhibitor of cancer cell colony formation. J Med Chem 1995; 38: 1053-1056.
28. Fang X, Yu S, Eder A, Mao M, Bast Jr RC, Boyd D et al. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 1999; 18: 6635-6640.
29. Hengartner G. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
30. Simpsons L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res 2001; 264: 29-41.
31. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 1998; 281: 2042-2045.
32. Chou MM, Hou W, Johnson J, Graham LK, Lee MH, Chen CS et al. Regulation of protein kinase C ζ by PI 3-kinase and PDK-1. Curr Biol 1998; 8: 1069-1077.
33. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17: 615-675.
34. Kim M-S, Lim W-K, Cha J-G, An N-H, Yoo S-J, Park J-H et al. The activation of PI 3-K and PKC ζ in PMA-induced differentiation of HL-60 cells. Cancer Lett 2001; 171: 79-85.
35. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. P70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 2001; 98: 9666-9670.
36. Pullen N, Thomas G et al. The modular phosphorylation and activation of p70S6K. FEBS Lett 1997; 410: 78-82.
37. Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA et al. Phosphorylation and activation of p70S6K by PDK1. Science 1998; 279: 673-674.
38. Alessi DR, Kozlowski MT, Weng QP, Morrice N, Avruch J. 3-phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70S6 kinase in vivo and in vitro. Curr Biol 1998; 8: 69-81.
39. Skorski T, Kanakaraj, Nieborowska-Skorska M, Ratjczak MZ, Wen R-C, Zon G et al. Phosphatidylinositol 3-kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726-736.
40. Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of ST571. Oncogene 2002; 21: 5868-5876.
41. Riordan FA, Bravery CA, Mengubas K, Ray N, Borthwick NJ, Akbar AN et al. Herbimycin A accelerates the induction of apoptosis following etoposide treatment or γ-irradiation of bcr-abl-positive leukaemia cells. Oncogene 1999; 16: 1533-1542.
42. Higginbottom K, Cummings M, Newland AC, Allen PD. Etoposide-mediated deregulation of the G2M checkpoint in myeloid leukaemic cell lines results in loss of cell survival. Br J Haematol 2002; 119: 956-964.
43. Hietakangas V, Poukkula M, Heiskanen KM, Karvinen JT, Sistonen L, Eriksson JE. Erythroid differentiation sensitizes K562 leukemia cells tp TRAIL-induced apoptosis by down-regulation of c-FLIP. Mol Cell Biol 2003; 23: 1278-1291.
44. Plo I, Bettaïeb A, Payrastre B, Mansat-De Mas V, Bordier C, Rousse A et al. The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukaemia cell lines. FEBS Lett 1999; 452: 150-154.
45. Freeburn RW, Wright KL, Burgess SJ, Astoul E, Cantrell DA, Ward SG. Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors. J Immunol 2002; 169: 5441-5450.
46. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001; 344: 1031-1037.
47. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986-3997.
48. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001; 98: 795-804.
49. Tari AM, Lim SJ, Hung M, Esteva FJ, Lopez-Berestein G. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene 2002; 21: 5224-5232.
50. Pene F, Claessens YE, Muller O, Viguie F, Mayeux P, Dreyfus F et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase in the proliferation and apoptosis in multiple myeloma. Oncogene 2002; 21: 6587-6597.
51. Dahia PL, Aguiar RC, Alberta J, Kum JB, Caron S, Sill H et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet 1999; 8: 185-193.
52. Aggerholm A, Grønbæk K, Guldberg P, Hokland P. Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorder. Eur J Haematol 2000; 65: 109-113.
53. Liu TC, Lin PM, Chang JG, Lee JP, Chen TP, Lin SF. Mutational analysis of PTEN/MMAC1 in acute myeloid leukemia. Am J Hematol 2000; 63: 170-175.
54. Yamada KM, Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 2001; 114: 2375-2382.
55. Aksoy IA, Ramsey MJ, Fruman DA, Aksoy S, Cantley LC, Tucker JD et al. Mouse phosphoinositide 3-kinase p110α gene: cloning, structural organization, and localization to chromosome 3 band B. Biochem Biophys Res Commun 1999; 262: 438-442.
56. Testoni N, Borsaru G, Martinelli G, Carboni C, Ruggeri D, Ottavian E et al. 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features. Haematologica 1999; 84: 690-694.
57. Luo J-M, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno K et al. Possibile dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 2003; 17: 1-8.
58. Krystal G, Damen JE, Helgason CD, Huber M, Hughes MR, Kalesnikoff J et al. SHIPs ahoy. Int J Biochem Cell Biol 1999; 31: 1007-1010.
59. Coggeshall KM, Nakamura K, Phee H. How protein phosphatases work? Mol Immunol 2002; 39: 521-529.
60. 2 is required for PKB phosphorylation at Ser-473. J Biol Chem 2002; 277: 9027-9035.
61. Zittoun RA, Mandelli F, Willemze R, De Witte T, Labar B, Resegoti L et al. Autologous or allogeneic bone marrow transplantations compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217-223.
62. Du L, Smolewski P, Bedner E, Traganos F, Darzynkiewicz Z. Selective protection of mitogenicaly stimulated human lymphocytes but not leukemic cells from cytosine arabinoside-induced apoptosis by LY294002, a phosphoinositol-3 kinase inhibitor. Int J Oncol 2001; 19: 811-819.
63. Kozikowski AP, Sun H, Brognard J, Dennis PA. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J Am Chem Soc 2003; 125: 1144-1145.